Ironwood Pharmaceuticals, Inc. (IRWD)
| Market Cap | 684.84M |
| Revenue (ttm) | 296.15M |
| Net Income (ttm) | 24.02M |
| Shares Out | 163.06M |
| EPS (ttm) | 0.15 |
| PE Ratio | 28.30 |
| Forward PE | 3.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,687,080 |
| Open | 4.010 |
| Previous Close | 4.040 |
| Day's Range | 3.970 - 4.350 |
| 52-Week Range | 0.527 - 5.780 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 7.67 (+82.62%) |
| Earnings Date | May 11, 2026 |
About IRWD
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C ... [Read more]
Financial Performance
In 2025, Ironwood Pharmaceuticals's revenue was $296.15 million, a decrease of -15.72% compared to the previous year's $351.41 million. Earnings were $24.02 million, an increase of 2629.20%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price target is $7.67, which is an increase of 82.62% from the latest price.
News
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
LINZESS is projected to deliver over $1.1 billion in U.S. net sales in 2026, supporting strong profitability and funding for apraglutide's development. Apraglutide's confirmatory Phase III trial will begin in Q2, targeting a 2029 NDA submission, with commercial launch preparations leveraging LINZESS experience.
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March ...
Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025
LINZESS achieved strong demand growth and expanded its pediatric indication, while a list price reduction and improved payer access are expected to drive over 30% net sales growth in 2026. Apraglutide advances with a pivotal Phase III trial, targeting >$700M U.S. peak sales.
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. East...
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta
CALGARY, AB / ACCESS Newswire / October 24, 2025 / Ironwood Stair & Rail Inc., a company built on craftsmanship and passion, has been recognised with the 2025 Consumer Choice Award in the Stairs and R...
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025
LINZESS maintains strong growth and profitability, with increased EBITDA guidance and a focus on transitioning to OTC. Apraglutide shows promising clinical results, though a confirmatory trial is required. Strategic alternatives are under review to maximize asset value.
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and r...
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intest...
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointe...
Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund
SAN ANTONIO--(BUSINESS WIRE)--Ironwood Midstream Energy Partners III, LLC (Ironwood III) today announced it has secured a substantial equity commitment from Kayne Anderson Energy Infrastructure Fund, ...
Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024
Strong 2024 results driven by LINZESS growth and disciplined expense management, with $916M net sales and robust cash flow supporting apraglutide advancement. Apraglutide’s NDA submission is underway, targeting Q3 2025 completion, while 2025 guidance anticipates high single-digit LINZESS demand growth amid pricing headwinds.
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Easte...
Ironwood Pharmaceuticals Transcript: Status Update
Apraglutide is prioritized as the next growth driver, with NDA submission delayed to Q3 2025 to include compelling long-term data. LINZESS faces pricing headwinds, prompting a 50% workforce reduction and a shift to a more targeted commercial model. 2025 guidance reflects these strategic changes.
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in...
Ironwood Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference
Debt has been reduced by $200M since the VectivBio acquisition, with further paydown planned as apraglutide launches in early 2026. LINZESS remains dominant but faces pricing headwinds, prompting a shift in contracting and promotion strategy. Apraglutide targets a validated, largely untapped market with a strong clinical profile and broad indication expected.